Skip to main content

Market Overview

D. Medical Receives CE Mark Approval for "Spring Zone" Durable Insulin Pump


D. Medical Industries Ltd. (Nasdaq: DMED) today announced that the Company, through its wholly owned subsidiary Spring Health Solution Ltd., received a CE Mark approval for its Spring™ Zone Insulin Delivery System. "Spring Zone" replaces D. Medical's first generation Spring ADI insulin pump.

The proprietary Intellispring™ technology at the heart of the "Spring Zone" Insulin Delivery System results in unique performance advantages such as superior blockage and detachment detection, environmental (pressure and temperature) adaptability and continuous insulin dose delivery check. This mechanism, backed by the Total Line Control™ (TLC) safety check system, enables failsafe operation and exceptional reliability for continuously controlled and monitored insulin delivery.


Related Articles (DMED)

View Comments and Join the Discussion!

Posted-In: News FDA Global

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at